In 2021, adoptive cell therapy (ACT) research reached a new high. See other ACT trends over the past five years.
Q3 2023 saw 3,866 therapies in development; 53% of those were gene therapies, 25% RNA therapies, and 22% non-genetically modified cell therapies.
The first Cell and Gene Therapy Regulatory Report from Citeline and ISCT provides a global overview of the cell and gene therapy landscape.
In this overview, we look at the clinical trial landscape for trials that had data presented at ESMO 2023.
